Life Sciences Industry Report - Part 7

The importance of biosimilars only continues to grow, driven by the potential savings they are able to deliver to healthcare systems, providing an alternative to comparator products and lowering price through competition.
In Europe, for example, where authorities acted quickly to ingrain these treatments into the regulatory framework, biosimilars have managed to provide tens of billions of euros in savings since 2012, according to IQVIA. When the primary patent on a blockbuster drug expires, affordable generic or biosimilar competition is expected to balance the market, offering relief to patients who could not afford the high price tag associated with the brand-name drug. However, in reality, this is not always the case.
In Part 7 – the final instalment of our inaugural Life Sciences Industry Report – we look more closely at reporting from 2024 on the biosimilar and generics space, providing an overview of the landscape and the potential yet to be realised therein, as well as the caveats to possibilities.
From how the US Inflation Reduction Act can provide a positive boost to biosimilars and how drugmakers ‘game’ the US patent system, to the complexities of navigating the market for these therapies when it comes to rare and complex conditions, as well as innovations on the horizon in generics – some industry analysts suggest that less expensive biosimilars may be the solution to free up finances for novel, more expensive agents.
In pharmaphorum’s inaugural Life Sciences Industry Report 2025, Parts 1 through 7, we delved into the trends that propelled the pharmaceutical industry along in 2024, aiming to present truly informed insights into an industry very much at the height of its discovery and development capabilities, on the precipice of truly impressive, paradigm shifting innovation and, vitally, paving the way to broader access to treatments that will permit better quality of life and patient outcomes overall.
Where will we be as we enter 2026? Time shall tell. Be part of the conversation, and get in touch about our Life Sciences Industry Report 2026 today.